Trauson Holdings: China's next med device M&A target

Trauson Holdings, China's largest maker of pelvic reconstruction plates and other trauma surgery-related orthopedic products, is likely one of the next big medical device acquisition targets in that country, Bloomberg predicts. The reason: Trauson is in a space that stands to gain as China's massive elderly population expands in the coming years. Medtronic ($MDT) is already thinking ahead in this way, the article notes, with its recent $755 million purchase of China Kanghui Holdings, an orthopedic implant maker. China's orthopedic implant sales will virtually double by 2015, to $2.7 billion, according to Frost & Sullivan data cited by Bloomberg. More than 181 million senior citizens in China have artificial joints and implanted spinal devices, according to the story. Story

Suggested Articles

The AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.